Copeland Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Copeland Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-38	Closed	-$2.21K	–	280
2023 Q3	$2.21K	Hold	38	–	–	﹤0.01%	275
2023 Q2	$2.43K	Hold	38	–	–	﹤0.01%	292
2023 Q1	$3K	Hold	38	–	–	﹤0.01%	236
2022 Q4	$3K	Hold	38	–	–	﹤0.01%	239
2022 Q3	$3K	Hold	38	–	–	﹤0.01%	225
2022 Q2	$3K	Hold	38	–	–	﹤0.01%	228
2022 Q1	$3K	Hold	38	–	–	﹤0.01%	238
2021 Q4	$2K	Hold	38	–	–	﹤0.01%	268
2021 Q3	$2K	Hold	38	–	–	﹤0.01%	265
2021 Q2	$3K	Hold	38	–	–	﹤0.01%	229
2021 Q1	$2K	Hold	38	–	–	﹤0.01%	262
2020 Q4	$2K	Hold	38	–	–	﹤0.01%	254
2020 Q3	$2K	Hold	38	–	–	﹤0.01%	227
2020 Q2	$2K	Hold	38	–	–	﹤0.01%	213
2020 Q1	$2K	Buy	+38	New	+$2.32K	﹤0.01%	209

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Copeland Capital Management's BMY Position: Q4 2023 in Review

Copeland Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 38 shares — an estimated $2.21K sold.

Copeland Capital Management first reported a position in BMY in Q1 2020 and held it in 15 quarters. The position peaked at $3K in Q1 2023. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Copeland Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Copeland Capital Management sold 38 Bristol-Myers Squibb shares in Q4 2023, an estimated $2.21K.
Copeland Capital Management first reported a position in Bristol-Myers Squibb in Q1 2020 and held it in 15 quarters.
Copeland Capital Management's Bristol-Myers Squibb position peaked at $3K in Q1 2023.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Copeland Capital Management's 13F filing for Q4 2023, filed 19 Jan 2024.